ClinicalTrials.gg
CompletedNCT03644485Updated Oct 31, 2024

Clinical Outcome of Delayed or Standard Prograf Together With Induction Therapy Followed by Conversion to Advagraf in Donation After Cardiac (or Circulatory) Death (DCD) Kidney Transplant Recipients

A Phase 4 interventional study of Tacrolimus immediate-release formulation and Tacrolimus prolonged-release formulation in Kidney Transplant, sponsored by Astellas Pharma China, Inc.. Completed at 14 sites in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-10-31.

Sponsored by Astellas Pharma China, Inc. (part of Astellas Pharma Inc) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
284
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The purpose of this study is to confirm non-inferiority of delayed Prograf treatment to standard Prograf treatment in the incidence of delayed graft function (DGF) within 1 week between the 2 immunosuppressive (IS) treatment groups: delayed or standard Prograf together with induction therapy, and then convert to Advagraf usage in donation after cardiac (or circulatory) death (DCD) kidney transplant recipients.

This study will also compare the clinical outcome within 6 month post-transplant between the 2 IS treatment groups and compare the safety throughout study period between the 2 IS treatment groups.

02

Conditions studied

  • Kidney Transplant

Keywords

  • kidney transplant
  • Tacrolimus
  • Prograf
  • Advagraf
  • FK506
03

In context

Lead sponsor

Astellas Pharma China, Inc. is the lead sponsor of 24 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject has end-stage kidney disease who is a suitable candidate for primary DCD kidney transplantation.
  • Subject is a resident of China.
  • Subject is scheduled to undergo DCD renal allograft transplantation with compatible ABO blood type.
  • Subject has peak panel-reactive antibodies (PRA) \< 10% or "Negative" test result.
  • Subject must be a recipient of a DCD kidney and receive the organ distributed by China Organ Transplant Response System only.
  • Female subject must either:

    • Be of non-: (defined as at least 1 year without any menses for which there is no other obvious pathological or physiological cause) prior to screening, or documented surgically sterile
    • Or, if of childbearing potential: Agree not to try to become pregnant throughout the study period and have a negative blood pregnancy test at screening.
  • A sexually active male or female subject is utilizing highly effective forms of starting at screening and throughout the study period if the risk of conception exists.
  • Subject agrees not to participate in another interventional study while participating in the present study from 1 month before randomization to 1 month after the last dose of drug.

Exclusion criteria

Exclusion Criteria:

  • Subject has previously received or is receiving an organ transplant other than kidney.
  • Subject is receiving double-kidney transplant.
  • Recipients of Maastricht Class I, II, and V donor organs.
  • Recipients of Maastricht Class III and IV donor organs without a full complement of intensive care unit and intraoperative records.
  • Subject has cold ischemia time of allograft > 24 hours before kidney transplantation surgery.
  • Subject has known to administration of tacrolimus (Prograf or Advagraf), or other macrolides.
  • Subject is unlikely to comply with the visits scheduled in the protocol or has a history of non-compliance.
  • Subject has evidence of active liver disease or the presence of a chronic active or C within 1 month prior to kidney transplant surgery.
  • Recipient or donor is seropositive for .
  • Subject has active systemic infection requiring the use of antimicrobial agents within 1 week prior to kidney transplant surgery.
  • Subject has current or a history of malignancy (within the past 5 years), except non- basal or squamous cell carcinoma of the skin or carcinoma in-situ of the cervix that has been treated successfully.
  • Subject has medical or psychological conditions which would preclude compliance with the study requirements.
  • Subject has any condition, including any uncontrolled disease state other than end-stage kidney disease, that constitutes an inappropriate risk or a contraindication for participation in the study, or that could interfere with the study objectives, conduction, or evaluation.
  • Female subject who breastfeed or donate ova starting at screening and throughout the study period.
  • Male subject who donate sperm starting at screening and throughout the study period.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
284 participants (actual)

Study arms

  • Experimental
    Standard Prograf group

    Participants received from day 1 tacrolimus immediate-release formulation (Prograf) 0.1 - 0.15 milligrams/kilograms/day (mg/kg/day) orally at 12-hour interval (twice daily 1 hour before meal or 2 hours after meal) for approximately 1 month. At 1 month after Kidney transplant, Prograf was converted to Advagraf on a 1:1 (mg: mg) total daily dose basis. The Advagraf was administered orally once daily in the morning, 1 hour before the breakfast; the whole blood target trough level for Advagraf was maintained as 6 - 12 nanograms/milliliter(ng/mL) within months 2 to 3, and 6 - 8 ng/mL within months 4 to 6.

    Drug: Tacrolimus immediate-release formulation · Drug: Tacrolimus prolonged-release formulation · Drug: Induction therapy · Drug: Mycophenolic acid drugs · Drug: Corticosteroids

  • Experimental
    Delayed Prograf group

    Participants received from day 3 to 5 Prograf 0.1 - 0.15 mg/kg/day orally at 12-hour interval (twice daily 1 hour before meal or 2 hours after meal) for approximately 1 month. At 1 month after Kidney transplant, Prograf was converted to Advagraf on a 1:1 (mg: mg) total daily dose basis. The Advagraf was administered orally once daily in the morning, 1 hour before the breakfast; the whole blood target trough level for Advagraf was maintained as 6 - 12 ng/mL within months 2 to 3, and 6 - 8 ng/mL within months 4 to 6.

    Drug: Tacrolimus immediate-release formulation · Drug: Tacrolimus prolonged-release formulation · Drug: Induction therapy · Drug: Mycophenolic acid drugs · Drug: Corticosteroids

Interventions

  • oral

    Also known as: Prograf, FK506

  • oral

    Also known as: Advagraf, FK506

  • DrugInduction therapy

    All participants will receive induction therapy. The dosage and administration of induction immunotherapy will be a single kind of drug determined by the investigator.

  • DrugMycophenolic acid drugs

    All participants will receive mycophenolic acid drugs in combination with corticosteroids. The dosage and administration of mycophenolic acid will be determined by the investigator.

  • DrugCorticosteroids

    All participants will receive corticosteroids in combination with mycophenolic acid drugs. The dosage and administration of corticosteroids will be determined by the investigator.

06

What researchers measure

Primary outcomes

  1. Incidence of delayed graft function (DGF)

    DGF is defined as dialysis requirement during the first post-transplant week (7 days).

    Time frame: Up to Day 7 after transplantation

Secondary outcomes

  1. Incidence of acute rejection (AR)

    The reporting of AR includes any biopsy-proven or clinically-suspected rejection of a subject after transplantation.

    Time frame: Up to Month 6 after transplantation

  2. Renal function assessed by estimated glomerular filtration rate (eGFR)

    eGFR will be derived using the abbreviated Modification of Diet in Renal Disease (MDRD) formula.

    Time frame: Up to Month 6 after transplantation

  3. Renal function assessed by serum creatinine

    Serum creatinine will be measured from serum sample collected.

    Time frame: Up to Month 6 after transplantation

  4. Renal function assessed by urea nitrogen

    Urea nitrogen will be measured from serum sample collected.

    Time frame: Up to Month 6 after transplantation

  5. Subject survival

    Subject survival is the time from the date of transplantation to the date of death or the date of the last follow-up. Subject survival will be estimated using Kaplan Meier estimates and compared by log rank test.

    Time frame: Up to Month 6 after transplantation

  6. Graft survival

    Graft survival is an estimate of the probability of the transplant functioning at a finite time after transplantation. Graft survival will be calculated from the date of transplantation to the date of irreversible graft failure or the date of the last follow-up during the period when the transplant is still functioning or to the date of death.

    Time frame: Up to Month 6 after transplantation

  7. Safety assessed by incidence of treatment-emergent adverse events (TEAEs)

    Adverse events (AEs) will be coded using the latest version of MedDRA. TEAE is defined as any AE following the transplantation until the end of the study.

    Time frame: Up to Month 7 after transplantation

  8. Safety assessed by incidence of serious adverse events (SAEs)

    AE is considered "serious" if the investigator or sponsor view any of the following outcomes: Death, life-threatening, persistent or significant disability/incapacity, congenital anomaly or birth defect, hospitalization, or medically important event.

    Time frame: Up to Month 7 after transplantation

  9. Number of participants with laboratory test abnormalities and/or AEs

    Number of participants with potentially clinically significant laboratory values.

    Time frame: Up to Month 7 after transplantation

  10. Number of participants with vital sign abnormalities and/or AEs

    Number of participants with potentially clinically significant vital sign values.

    Time frame: Up to Month 7 after transplantation

  11. Number of participants with 12-lead electrocardiograms (ECG) abnormalities and/or AEs

    ECG will be performed in the supine position after the subject has been breathing quietly for 5 minutes. Any clinically significant adverse changes on the ECG will be reported as AEs.

    Time frame: Up to Month 7 after transplantation

07

Study locations

14 sites
  • Site CN08608
    Beijing, China
  • Site CN08619
    Beijing, China
  • Site CN08609
    Changsha, China
  • Site CN08604
    Guangzhou, China
  • Site CN08614
    Hangzhou, China
  • Site CN08617
    Hangzhou, China
  • Site CN08610
    Nanjing, China
  • Site CN08618
    Nanjing, China
  • Site CN08612
    Shanghai, China
  • Site CN08603
    Tianjin, China
  • Site CN08621
    Wenzhou, China
  • Site CN08602
    Wuhan, China
  • Site CN08613
    Wuhan, China
  • Site CN08605
    Xi'an, China
08

References and documents

Individual participant data

Plan to share: No — Access to anonymized individual participant level data will not be provided for this trial. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Jul 2022, 44 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 22, 2018
First posted
Aug 23, 2018
StartActual
Oct 21, 2018
Primary completionActual
Jul 15, 2022
CompletionActual
Jul 15, 2022
Last update
Oct 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03644485
Responsible party
Sponsor
First posted
Aug 23, 2018
Start date
Oct 21, 2018
Primary completion
Jul 15, 2022
Completion
Jul 15, 2022
Last update
Oct 31, 2024

Study contacts

Medical Director
study director · Astellas Pharma China, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tacrolimus

Start the discussion